MPLX LP
MPLXMPLX LP is strength at full price. The numbers are improving — and a P/E at the 93rd percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 93rd percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (46 weeks in) while the P/E sits at the 93rd percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +2.8% year on year, and 130% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
MPLX LP trades at $57.9, in a confirmed uptrend and 46 weeks into that stage. That is +2.3% against its own 200-day average. It sits at 84% of a 52-week range of $48 to $60. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 7 straight weeks.
Today the stock is in a confirmed uptrend — week 46 of stage 2. At $57.9 it trades +2.3% versus its 200-day average and sits at 84% of its 52-week range ($48–$60).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +76% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 7 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
MPLX LP trades at 12.5× P/E, at the pricey end of its own range (93rd percentile). Its long-run median P/E is 10.6×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 12.5× is at the pricey end of its own range (93rd percentile), against a long-run median of 10.6× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +14.5% against a +15.1% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +18.3%/yr price move, ~+5.5%/yr came from earnings growth and ~+12.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
MPLX LP reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 12.6% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +6.4% | +2.0% | — | — |
| Profit | +13.5% | +7.5% | — | — |
| EPS | +14.5% | +8.7% | — | — |
| Stock price | +15.1% | +18.3% | +15.1% | +6.0% |
4-Factor Sector Score
40.8/100 — rank 22 of 30 in Oil & Gas Midstream · 85% evidence confidence
MPLX LP scores 40.8 out of 100 against the 30 companies it is compared with in Oil & Gas Midstream, ranking 22. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 12.2 + 12.6 + 11.1 + 4.9 = 40.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
MPLX LP reported $3.1 B of revenue in the Jun 26 quarter, +10.6% year on year. Over 4 years it has compounded at 5.0% a year. The last full year, FY25, came in at $11.8 B. The last four reported quarters add to $12.0 B.
FY25 revenue came in at $11.8 B (+6.4% on the year), capping 4 years at 5.0% compound. The latest quarter (Jun 26) printed $3.1 B, +10.6% year on year.
Pace check: the last four quarters averaged +4.9% growth against the decade's 5.0% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +4.9% over the last 4 quarters against +4.8%/yr over the last 8 — stabilising; TTM profit +9.2% vs +5.6%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
MPLX LP's operating margin is 38.3% in the Jun 26 quarter, −1.3 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 37.8% to 40.3%. The current quarter sits inside that band.
The latest quarter's operating margin is 38.3%, −1.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 37.8%–40.3%, and FY25's 40.3% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −1.3 pp year on year while gross margin went −1.5 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
MPLX LP earned $1.1 B of net profit in the Jun 26 quarter, +2.8% year on year. Full-year FY25 profit was $5.0 B. The 4-year compound rate is 12.3%. That is 34.8% of the quarter's revenue. The same quarter a year earlier earned $1.1 B.
Jun 26 profit was $1.1 B, +2.8% year on year. On the full year, FY25 printed $5.0 B (+13.5%), and the 4-year compound rate is 12.3%.
Why profit moved: revenue contributed +10.6% and the margin −1.3 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +9.8% vs revenue +4.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 130% of MPLX LP's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $5.9 B of operating cash against $5.0 B of profit. After $1.8 B of capital spending, $4.1 B was left as free cash.
FY25: operating cash of $5.9 B against reported profit of $5.0 B, leaving free cash of $4.1 B after $1.8 B of capital spending. Across the last 3 fiscal years the conversion rate is 130% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
MPLX LP does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $4.0 B over the last 3 years. Averaged over those years that is 11.3% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $4.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
MPLX LP earns a ROE of 34% in FY25. That is up from a trough of 24% in FY21. Return on invested capital clears the cost of that capital by +6.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 41.9% net margin on 0.27× asset turns.
FY25 ROE is 34%, recovered from a FY21 trough of 24% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 41.9% net margin × 0.27× asset turns × 2.96× balance-sheet leverage ≈ 33.5% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 12.0% − 6.0% = a +6.0 pp spread. The 6.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
MPLX LP paid $4.31 per share over the last four reported quarters. The most recent declaration was $1.08 for Jun 26. Against the current price of $57.9 that is a trailing yield of 7.44%, measured on dividends already paid rather than on a forecast.
MPLX LP paid $4.31 per share across the last four reported quarters, most recently $1.08 for Jun 26. Against the current price of $57.9 the trailing twelve months work out to 7.44% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
MPLX LP carries total debt of $25.9 B against shareholder equity of $14.3 B as of Jun 26, a debt-to-equity of 1.82. On the annual view that ratio went from 1.45 in FY21 to 1.78 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $25.9 B against shareholder equity of $14.3 B — a debt-to-equity of 1.82. On the annual view, debt-to-equity went from 1.45 (FY21) to 1.78 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
2.0% of MPLX LP's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 2.0% of the float is sold short, and at typical trading volumes it would take about 5.7 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
MPLX LP: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Frontline plcFRO | 80.9/100Sector-leading setup81% evidence | BREAKING OUT | 29.2/35 Revenue 18.5% · PAT 100% · OPM change 60.1 pp 83% evidence | 16.8/25 ROCE 10.8% · OPM 81.9% 76% evidence | 15.5/20 P/E 8.6× · PEG 0.19 65% evidence | 19.4/20 RS sector 41.1% · RS bench 54.4% · 1Y 131.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 29.2 + 16.8 + 15.5 + 19.4 = 80.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2International Seaways, Inc.INSW | 78.2/100Favorable setup81% evidence | BREAKING OUT | 27.0/35 Revenue 14.5% · PAT 69.3% · OPM change 57.6 pp 83% evidence | 16.5/25 ROCE 11.2% · OPM 89.9% 76% evidence | 16.4/20 P/E 6.6× · PEG 0.09 65% evidence | 18.3/20 RS sector 32.3% · RS bench 44.6% · 1Y 129.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 27 + 16.5 + 16.4 + 18.3 = 78.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3BW LPG LimitedBWLP | 73.5/100Favorable setup81% evidence | BREAKING OUT | 24.7/35 Revenue 5.1% · PAT 31.4% · OPM change 23.6 pp 83% evidence | 14.5/25 ROCE 8% · OPM 26.2% 76% evidence | 15.4/20 P/E 7.3× · PEG 0.28 65% evidence | 18.9/20 RS sector 27.3% · RS bench 39.6% · 1Y 68.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 14.5 + 15.4 + 18.9 = 73.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Venture Global, Inc.VG | 69.6/100Favorable setup85% evidence | BREAKING OUT | 23.4/35 Revenue 100% · PAT 100% · OPM change 14.3 pp 95% evidence | 11.7/25 ROCE 4.3% · OPM 47.8% 76% evidence | 15.8/20 P/E 8.8× · PEG 0.14 65% evidence | 18.7/20 RS sector 10.9% · RS bench 21.1% · 1Y 10.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.4 + 11.7 + 15.8 + 18.7 = 69.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Cmb.Tech NVCMBT | 67.0/100Favorable setup71% evidence | BREAKING OUT | 24.0/35 Revenue 100% · PAT 12.5% · OPM change 40.9 pp 83% evidence | 12.7/25 ROCE 5.8% · OPM 84.6% 76% evidence | 11.2/20 P/E 7.9× · PEG — 15% evidence | 19.1/20 RS sector 27.5% · RS bench 40% · 1Y 113.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 12.7 + 11.2 + 19.1 = 67 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Cheniere Energy Partners, L.P.CQP | 66.7/100Favorable setup85% evidence | BREAKING OUT | 26.8/35 Revenue 15.4% · PAT 28.1% · OPM change 22.8 pp 95% evidence | 15.1/25 ROCE 8.5% · OPM 51.9% 76% evidence | 14.7/20 P/E 11.1× · PEG 0.33 65% evidence | 10.1/20 RS sector -7.3% · RS bench 2.7% · 1Y 25.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 26.8 + 15.1 + 14.7 + 10.1 = 66.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Scorpio Tankers Inc.STNG | 61.9/100Thin evidence · provisional58% evidence | TURNING | 23.1/35 Revenue — · PAT — · OPM change 42 pp 45% evidence | 14.9/25 ROCE 9.8% · OPM 70.2% 76% evidence | 11.5/20 P/E 4.3× · PEG — 15% evidence | 12.4/20 RS sector 4.5% · RS bench 15.2% · 1Y 45.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 14.9 + 11.5 + 12.4 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Cheniere Energy, Inc.LNG | 59.5/100Mixed-positive evidence85% evidence | BREAKING OUT | 19.8/35 Revenue 17.5% · PAT -11.8% · OPM change 20.3 pp 95% evidence | 14.8/25 ROCE 10.2% · OPM 74.8% 76% evidence | 12.0/20 P/E 17.8× · PEG 0.9 65% evidence | 12.9/20 RS sector -4.8% · RS bench 5.2% · 1Y 15.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.8 + 12 + 12.9 = 59.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Targa Resources Corp.TRGP | 57.3/100Mixed-positive evidence85% evidence | BREAKING OUT | 18.7/35 Revenue -2% · PAT 29.6% · OPM change 3.5 pp 95% evidence | 12.4/25 ROCE 5.4% · OPM 27.8% 76% evidence | 12.4/20 P/E 25.6× · PEG 0.51 65% evidence | 13.8/20 RS sector 7.3% · RS bench 17.7% · 1Y 73.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 12.4 + 12.4 + 13.8 = 57.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Energy Transfer LPET | 55.8/100Mixed-positive evidence85% evidence | BREAKING OUT | 20.3/35 Revenue 33.3% · PAT 16.1% · OPM change -1.6 pp 95% evidence | 10.5/25 ROCE 3% · OPM 10.4% 76% evidence | 12.3/20 P/E 13× · PEG 0.93 65% evidence | 12.7/20 RS sector -4.3% · RS bench 6.1% · 1Y 22%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 10.5 + 12.3 + 12.7 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Plains All American Pipeline, L.P.PAA | 52.8/100Mixed-positive evidence81% evidence | TURNING | 16.8/35 Revenue -7.1% · PAT 45.4% · OPM change 0.1 pp 83% evidence | 6.5/25 ROCE 1.7% · OPM 3.2% 76% evidence | 13.1/20 P/E 18.5× · PEG 0.49 65% evidence | 16.4/20 RS sector 4.1% · RS bench 14.8% · 1Y 49.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 6.5 + 13.1 + 16.4 = 52.8 · Decision use: Price leads the evidence: RS versus the benchmark is 14.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 12Western Midstream Partners, LPWES | 51.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 13.8/35 Revenue 11.4% · PAT -6.5% · OPM change -2.9 pp 83% evidence | 13.3/25 ROCE 3.8% · OPM 41.8% 76% evidence | 15.0/20 P/E 13.5× · PEG 0.17 65% evidence | 9.8/20 RS sector -6.6% · RS bench 3.7% · 1Y 22.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13.3 + 15 + 9.8 = 51.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Kinetik Holdings Inc.KNTK | 49.8/100Mixed-negative evidence81% evidence | BREAKING OUT | 15.5/35 Revenue 9.3% · PAT 100% · OPM change -5.2 pp 83% evidence | 4.7/25 ROCE -0.1% · OPM -0.9% 76% evidence | 14.0/20 P/E 19.8× · PEG 0.27 65% evidence | 15.6/20 RS sector 3.4% · RS bench 14% · 1Y 25.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 4.7 + 14 + 15.6 = 49.8 · Decision use: Price leads the evidence: RS versus the benchmark is 14%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Golar LNG LimitedGLNG | 49.4/100Mixed-negative evidence81% evidence | TURNING | 27.8/35 Revenue 81.5% · PAT 100% · OPM change 76.5 pp 83% evidence | 10.3/25 ROCE 2.7% · OPM 81.8% 76% evidence | 4.4/20 P/E 42.3× · PEG 2.76 65% evidence | 6.9/20 RS sector -7.1% · RS bench 2.4% · 1Y 28.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 27.8 + 10.3 + 4.4 + 6.9 = 49.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.1% and the one-year return is 28.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 15ONEOK, Inc.OKE | 47.9/100Mixed-negative evidence85% evidence | TURNING | 16.1/35 Revenue 40.8% · PAT 13.1% · OPM change -4.9 pp 95% evidence | 10.3/25 ROCE 2.7% · OPM 13.2% 76% evidence | 10.8/20 P/E 15× · PEG 1.15 65% evidence | 10.7/20 RS sector -5.3% · RS bench 4.6% · 1Y 29.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 10.3 + 10.8 + 10.7 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Hess Midstream LPHESM | 46.7/100Mixed-negative evidence81% evidence | TURNING | 12.2/35 Revenue 7% · PAT 3.6% · OPM change -1.1 pp 83% evidence | 14.8/25 ROCE 5.8% · OPM 61% 76% evidence | 11.8/20 P/E 13.4× · PEG 1.01 65% evidence | 7.9/20 RS sector -10% · RS bench -0.1% · 1Y 11.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 14.8 + 11.8 + 7.9 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Kinder Morgan, Inc.KMI | 46.4/100Mixed-negative evidence85% evidence | ASLEEP | 21.6/35 Revenue 12.5% · PAT 26.1% · OPM change 1.6 pp 95% evidence | 10.3/25 ROCE 2% · OPM 30.1% 76% evidence | 12.4/20 P/E 20.5× · PEG 0.73 65% evidence | 2.1/20 RS sector -14.9% · RS bench -5.7% · 1Y 12.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 10.3 + 12.4 + 2.1 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18The Williams Companies, Inc.WMB | 45.5/100Mixed-negative evidence85% evidence | ASLEEP | 22.1/35 Revenue 8.7% · PAT 26.2% · OPM change 4.7 pp 95% evidence | 10.9/25 ROCE 2.3% · OPM 38.7% 76% evidence | 9.7/20 P/E 29.6× · PEG 1.11 65% evidence | 2.8/20 RS sector -12.8% · RS bench -3.5% · 1Y 18%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 10.9 + 9.7 + 2.8 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Plains GP Holdings, L.P.PAGP | 43.4/100Mixed-negative evidence64% evidence | BREAKING OUT | 12.8/35 Revenue -7.1% · PAT — · OPM change 0.1 pp 62% evidence | 4.0/25 ROCE 1.6% · OPM 3.2% 76% evidence | 9.4/20 P/E 25× · PEG — 15% evidence | 17.2/20 RS sector 5.6% · RS bench 16.3% · 1Y 51.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 4 + 9.4 + 17.2 = 43.4 · Decision use: Price leads the evidence: RS versus the benchmark is 16.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Pembina Pipeline CorporationPBA | 43.3/100Mixed-negative evidence85% evidence | TURNING | 9.5/35 Revenue -1.3% · PAT -4.2% · OPM change 0 pp 95% evidence | 14.6/25 ROCE 7.7% · OPM 34% 76% evidence | 13.3/20 P/E 23.1× · PEG 0.33 65% evidence | 5.9/20 RS sector -8.9% · RS bench 0.9% · 1Y 17.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 9.5 + 14.6 + 13.3 + 5.9 = 43.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21South Bow CorporationSOBO | 42.7/100Mixed-negative evidence81% evidence | ASLEEP | 12.7/35 Revenue -4.6% · PAT 44.5% · OPM change -3.1 pp 83% evidence | 9.8/25 ROCE 1.7% · OPM 32.6% 76% evidence | 13.5/20 P/E 16.4× · PEG 0.36 65% evidence | 6.7/20 RS sector -6.1% · RS bench 3.7% · 1Y 27.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 9.8 + 13.5 + 6.7 = 42.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22MPLX LPthis pageMPLX | 40.8/100Mixed-negative evidence85% evidence | BREAKING OUT | 12.2/35 Revenue 4.8% · PAT 9.6% · OPM change -1.4 pp 95% evidence | 12.6/25 ROCE 3.2% · OPM 38.3% 76% evidence | 11.1/20 P/E 12.1× · PEG 1.16 65% evidence | 4.9/20 RS sector -12.5% · RS bench -2.6% · 1Y 15.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 12.6 + 11.1 + 4.9 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Enterprise Products Partners L.P.EPD | 40.6/100Mixed-negative evidence85% evidence | TURNING | 13.8/35 Revenue 6.8% · PAT 7.5% · OPM change -3.5 pp 95% evidence | 11.5/25 ROCE 3.5% · OPM 12.3% 76% evidence | 8.9/20 P/E 12.7× · PEG 1.8 65% evidence | 6.4/20 RS sector -9.4% · RS bench 0.4% · 1Y 20.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 11.5 + 8.9 + 6.4 = 40.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Antero Midstream CorporationAM | 40.4/100Thin evidence · provisional58% evidence | ASLEEP | 15.8/35 Revenue — · PAT — · OPM change -0.9 pp 45% evidence | 13.0/25 ROCE 3.1% · OPM 60% 76% evidence | 9.1/20 P/E 27.1× · PEG — 15% evidence | 2.5/20 RS sector -13% · RS bench -3.7% · 1Y 14%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 13 + 9.1 + 2.5 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25DT Midstream, Inc.DTM | 37.6/100Thin evidence · provisional58% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 10.7/25 ROCE 1.8% · OPM 49.4% 76% evidence | 8.6/20 P/E 32.1× · PEG — 15% evidence | 0.3/20 RS sector -18.9% · RS bench -10.1% · 1Y 16.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 10.7 + 8.6 + 0.3 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Viper Energy, Inc.VNOM | 35.4/100Mixed-negative evidence71% evidence | ASLEEP | 11.4/35 Revenue 84.3% · PAT -121.9% · OPM change -13.8 pp 83% evidence | 10.8/25 ROCE 2.8% · OPM 49.5% 76% evidence | 10.1/20 P/E 15.8× · PEG — 15% evidence | 3.1/20 RS sector -14.1% · RS bench -4.8% · 1Y 15.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.4 + 10.8 + 10.1 + 3.1 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27TC Energy CorporationTRP | 34.0/100Adverse evidence85% evidence | ASLEEP | 13.0/35 Revenue 9.7% · PAT -14.8% · OPM change 0.9 pp 95% evidence | 8.3/25 ROCE 1.6% · OPM 44.3% 76% evidence | 11.9/20 P/E 28.1× · PEG 0.7 65% evidence | 0.8/20 RS sector -15.3% · RS bench -6.1% · 1Y 16.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 8.3 + 11.9 + 0.8 = 34 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Excelerate Energy, Inc.EE | 31.7/100Adverse evidence81% evidence | FADING | 13.6/35 Revenue 39.4% · PAT -6.8% · OPM change -2 pp 83% evidence | 8.9/25 ROCE 2.5% · OPM 18.9% 76% evidence | 4.0/20 P/E 27.2× · PEG 3.91 65% evidence | 5.2/20 RS sector -9% · RS bench 0.5% · 1Y 49.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 8.9 + 4 + 5.2 = 31.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Enbridge Inc.ENB | 24.3/100Adverse evidence85% evidence | BASING | 13.4/35 Revenue 29.5% · PAT -8% · OPM change -5.5 pp 95% evidence | 6.4/25 ROCE 1.4% · OPM 9.9% 76% evidence | 4.2/20 P/E 29.7× · PEG 2.88 65% evidence | 0.3/20 RS sector -20.8% · RS bench -12% · 1Y -2.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 6.4 + 4.2 + 0.3 = 24.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30SunocoCorp LLCSUNC | 50.8/100Thin evidence · provisional23% evidence | BREAKING OUT | 18.4/35 Revenue — · PAT — · OPM change 2.3 pp 10% evidence | 12.4/25 ROCE 6.8% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 18.4 + 12.4 + 10 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is MPLX LP's stock price today?
MPLX LP trades at $57.9, +15.1% over the past year. The company is valued at $59.0 B. The stock sits at 84% of its 52-week range of $48–$60, +2.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 46 weeks in. — as of 17 September 2026.
What were MPLX LP's latest quarterly results?
MPLX LP reported revenue of $3.1 B and net profit of $1.1 B for the Jun 26 quarter. Revenue rose 10.6% and profit rose 2.8% year on year. Earnings per share were $1.06. The operating margin was 38.3%, 1.3 pp lower than a year earlier. — as of 17 September 2026.
What is MPLX LP's revenue?
MPLX LP reported revenue of $3.1 B in the Jun 26 quarter, +10.6% year on year. For the full FY25 fiscal year, revenue was $11.8 B (+6.4%). Over the last 4 years revenue compounded at 5.0% a year. — as of 17 September 2026.
What is MPLX LP's profit?
MPLX LP earned $1.1 B of net profit in the Jun 26 quarter, +2.8% year on year. Full-year FY25 profit was $5.0 B. The operating margin ran 38.3% in the latest quarter. — as of 17 September 2026.
What is MPLX LP's market cap?
MPLX LP's market capitalisation is $59.0 B at a stock price of $57.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is MPLX LP's P/E ratio?
MPLX LP trades at a P/E of 12.5×, at the 93rd percentile of its own 5-year range, against a long-run median of 10.6×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does MPLX LP pay a dividend?
Yes — MPLX LP declared $1.08 per share for Jun 26, and $4.31 per share across the last four reported quarters. — as of 17 September 2026.
What is MPLX LP's dividend per share?
MPLX LP's most recently declared dividend is $1.08 per share for Jun 26, giving $4.31 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is MPLX LP's dividend yield?
MPLX LP's trailing dividend yield is 7.44%: $4.31 declared per share across the last four reported quarters, against a share price of $57.9. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is MPLX LP overvalued?
On its own history, MPLX LP looks expensive: its P/E of 12.5× sits at the 93rd percentile of its 5-year range (long-run median 10.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 17 September 2026.
Is MPLX LP growing?
Yes — MPLX LP is growing: latest-quarter revenue +10.6% year on year, profit +2.8%, and the margin −1.3 pp at 38.3%. The 4-year compound rates are 5.0% (revenue) and 12.3% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is MPLX LP performing?
MPLX LP is in a confirmed uptrend, 46 weeks in. Its latest quarter's revenue rose 10.6% and profit rose 2.8% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is MPLX LP in?
Mixed — the growth curves are steadily positive, but ROCE at 12.6% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +4.9% latest, profit growth +9.2% latest, eps growth +10.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is MPLX LP in an uptrend?
Yes — the price is in a confirmed uptrend (week 46 of stage 2), trading +2.3% versus its 200-day average and at 84% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is MPLX LP beating the market?
On recent form, yes — MPLX LP has been ahead of the S&P 500 on a trailing-13-week view for 7 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +76% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will MPLX LP's stock price go up?
This page publishes no price forecast for MPLX LP. What it measures instead: the stock price is $57.9, the price is in a confirmed uptrend 46 weeks in. Its P/E of 12.5× sits at the 93rd percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against MPLX LP?
Somewhat — short interest is 2.0% of MPLX LP's tradable float, about 5.7 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does MPLX LP have too much debt?
It carries real leverage — MPLX LP's debt-to-equity is 1.83. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is MPLX LP's capex?
MPLX LP spent $4.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.8 B. — as of 17 September 2026.
What is MPLX LP's cash flow?
MPLX LP generated $5.9 B of operating cash flow in FY25 and $4.1 B of free cash flow after $1.8 B of capital spending. Reported profit that year was $5.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is MPLX LP's profit real cash?
Yes — over the last 3 fiscal years, 130% of MPLX LP's reported profit arrived as operating cash. In FY25, operating cash was $5.9 B against reported profit of $5.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
Where is MPLX LP in its business cycle?
MPLX LP's FY25 operating margin was 40.3%, against a 5-year band of 37.8%–40.3%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 38.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the MPLX LP story?
The sharpest disagreement: the engine is strong, but at the 93rd percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is MPLX LP a stock worth studying right now?
This is not investment advice. The machine read: MPLX LP is strength at full price. The numbers are improving — and a P/E at the 93rd percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!